Inhibitors of lysine gingipain
The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis , including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
1. A compound according to the formula:
or a pharmaceutically acceptable salt thereof, wherein
Z is selected from the group consisting of benzothiazol-2-yl-carbonyl, pyridin-2-yl-carbonyl, and thiazol-2-yl-carbonyl; and
R 3 is selected from the group consisting of cyclohexyl, cyclopentyl, morpholino, phenyl, piperidinyl, pyridinyl, oxodihydropyridinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydronaphthyl, and thiazolyl,
wherein R 3 is optionally substituted with 1-3 members selected from the group consisting of methyl, methoxy, trifluoromethyl, acetyl, and —N 3 .
2. The compound of claim 1 , wherein R 3 is selected from the group consisting of cyclohexyl; 1-methylcyclohexyl; 1-methoxycyclohexyl; cyclopentyl; morpholin-2-yl; 4-acetylmorpholin-2-yl; phenyl; 2-trifluoromethylphenyl; 3-azidophenyl; piperidine-3-yl; 1-acetyl-piperidine-3-yl; pyridin-2-yl; pyridin-3-yl; pyridin-4-yl; 6-oxo-1,6-dihydropyridin-2-yl; tetrahydrofuran-2-yl; tetrahydro-2H-pyran-2-yl; tetrahydro-2H-pyran-3-yl; tetrahydro-2H-pyran-4-yl; 1,2,3,4-tetrahydronaphth-1-yl; 1,2,3,4-tetrahydronaphth-2-yl; thiazol-5-yl; and thiazol-2-yl.
3. The compound of claim 1 , having a structure according to the formula:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein
R 3 is selected from the group consisting of cyclohexyl; 1-methylcyclohexyl; 1-methoxycyclohexyl; cyclopentyl; morpholin-2-yl; 4-acetylmorpholin-2-yl; phenyl; 2-trifluoromethylphenyl; 3-azidophenyl; piperidine-3-yl; 1-acetyl-piperidine-3-yl; pyridin-2-yl; pyridin-3-yl; pyridin-4-yl; 6-oxo-1,6-dihydropyridin-2-yl; tetrahydrofuran-2-yl; tetrahydro-2H-pyran-2-yl; tetrahydro-2H-pyran-3-yl; tetrahydro-2H-pyran-4-yl; 1,2,3,4-tetrahydronaphth-1-yl; 1,2,3,4-tetrahydronaphth-2-yl; thiazol-5-yl; and thiazol-2-yl.
5. The compound of claim 1 , which is selected from the group consisting of
and pharmaceutically acceptable salts thereof.
6. The compound of claim 1 , which is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein
Z is selected from the group consisting of pyridin-2-yl-carbonyl and thiazol-2-yl-carbonyl.
8. The compound of claim 7 , which is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
9. The compound of claim 7 , which is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
10. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
11. A method of treating a disease or condition associated with P. gingivalis infection, the method comprising administering to a subject an effective amount of a compound according to the formula:
or a pharmaceutically acceptable salt thereof, wherein
Z is selected from the group consisting of benzothiazol-2-yl-carbonyl, pyridin-2-yl-carbonyl, and thiazol-2-yl-carbonyl; and
R 3 is selected from the group consisting of cyclohexyl, cyclopentyl, morpholino, phenyl, piperidinyl, pyridinyl, oxodihydropyridinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydronaphthyl, and thiazolyl,
wherein R 3 is optionally substituted with 1-3 members selected from the group consisting of methyl, methoxy, trifluoromethyl, acetyl, and —N 3 .
12. The method of claim 11 , wherein R 3 is selected from the group consisting of cyclohexyl; 1-methylcyclohexyl; 1-methoxycyclohexyl; cyclopentyl; morpholin-2-yl; 4-acetylmorpholin-2-yl; phenyl; 2-trifluoromethylphenyl; 3-azidophenyl; piperidine-3-yl; 1-acetyl-piperidine-3-yl; pyridin-2-yl; pyridin-3-yl; pyridin-4-yl; 6-oxo-1,6-dihydropyridin-2-yl; tetrahydrofuran-2-yl; tetrahydro-2H-pyran-2-yl; tetrahydro-2H-pyran-3-yl; tetrahydro-2H-pyran-4-yl; 1,2,3,4-tetrahydronaphth-1-yl; 1,2,3,4-tetrahydronaphth-2-yl; thiazol-5-yl; and thiazol-2-yl.
13. The method of claim 11 , wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
14. The method of claim 11 , wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
15. The method of claim 11 , wherein the disease or condition is selected from a brain disorder, periodontal disease, diabetes, a cardiovascular disease, arthritis, elevated risk of preterm birth, pneumonia, cancer, a kidney disease, a liver disease, a retinal disorder, and glaucoma.
16. The method of claim 15 , wherein the disease or condition is a brain disorder.
17. The method of claim 15 , wherein the brain disorder is selected from the group consisting of Alzheimer's disease, Down's syndrome, epilepsy, autism, Parkinson's disease, essential tremor, fronto-temporal dementia, progressive supranuclear palsy, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, mild cognitive impairment, age associated memory impairment, chronic traumatic encephalopathy, stroke, Lewy Body disease, multiple system atrophy, schizophrenia, and depression.
18. The method of claim 17 , wherein the brain disorder is Alzheimer's disease.
19. The method of claim 11 , wherein the compound is administered to the subject for at least one month.
20. The method of claim 11 , wherein the subject is a human, a canine, or a feline.